The FDA approved Pluvicto, a Novartis radiopharmaceutical, as a new treatment option for advanced prostate cancer. Novartis added the therapy via its $2.1 billion acquisition of Endocyte four years ago.
Intracranial brachytherapy was recently improved through the development of a surgically targeted radiation therapy comprised of Cesium-131 radiation seeds embedded in a bioresorbable collagen tile.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Novartis reported Phase 3 study results for a targeted radiation therapy showing that treatment helped patients with advanced prostate cancer live longer. The company will present data from this pivotal study during the annual meeting of the American Society of Clinical Oncology.
A French company is developing a technology that has the potential to magnify radiation doses without increasing damage to surrounding tissue.
There are myriad prostate cancer screeners on the market, but a San Diego company’s test has an interesting spin: Researchers have found that the results of GenomeDx’s Decipher diagnostic shifts the way physicians recommend treatment for the disease, as seen in a recent Red Journal paper. The company’s genomic test, which it’s commercializing now, predicts the probability […]